Vol. 6 No. 1 (2026)
Reimbursement Reviews

Trofinetide (Daybue)

decorative image of the issue cover

Published January 6, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Trofinetide (Daybue), 200 mg/mL, solution, oral or by gastrostomy tube.
  • Indication: For the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older and weighing at least 9 kg.